Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 3.125p 3.00p 3.25p 3.125p 3.125p 3.125p 69,183 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.7 -0.7 - 11.13

Hemogenyx Share Discussion Threads

Showing 1376 to 1399 of 1400 messages
Chat Pages: 56  55  54  53  52  51  50  49  48  47  46  45  Older
DateSubjectAuthorDiscuss
14/7/2018
23:43
I’ve been listening to Justin Waite on Vox podcasts. Good comments on Hemo and raising interest from investors again. Time to add a few more I think.
moormoney
13/7/2018
14:26
Added a few more today. Once the weak holders have gone there should be a nice share price run up towards CDX phase1.
badger60
13/7/2018
14:07
Yeah the humanised mice income alone and pending deals should see the share price circa 5-6p in the near term imo.
rathean
13/7/2018
09:03
Yep, very good price.
on target
13/7/2018
08:56
Added another 50k at 3.02p. Well placed ahead of the news.
rathean
06/7/2018
10:49
What news are you expecting cudmore?
on target
06/7/2018
10:25
NEWS IMMINENT!!!!!!
cudmore
05/7/2018
14:54
Agreed but they need to put a bit more effort into PR and promoting the product potential. In the meantime it's an ideal opportunity to top up while there's weak holders willing to take a loss.
badger60
05/7/2018
13:59
Found some loose change to add 30000 to my holding, anything below 4p is excellent value imo, happy to keep accumulating.
rathean
01/7/2018
23:14
What the hell goes on in your pocket?????.....lol.
lufc5
30/6/2018
20:25
I must apologies. I never post and therefore blame my pocket for the gibberish!!!. Not sure how it happened but when I saw my name I did wonder why!!!. I have invested in a few companies including Hemogynex and I think over the next 2 yrs there will be a decent return. Good luck to all invested here and I hope to read some more positive news.
siron38
29/6/2018
20:48
Your first post in 7 months and it's gibberish siron??
on target
29/6/2018
18:43
Ammmweep je .edu jury t
siron38
28/6/2018
19:27
This is going sub 1p soon.........still no news and investors getting impatient............ Might sell tomorrow and wait for 1p I'll get more bang for my pennies then.........lol
applegarthlse
28/6/2018
17:41
CAR-T therapy needs much more research and modification to solve the many toxicity issues before it can be used to treat cancer masses...ie tumours in organs etc..Also it currently costs circa $500k per treatment....with overall costs of up to $1mio per patient. ......and this is what makes Hemogenyx's novel BMT approach so exciting....... hTtps://cen.acs.org/pharmaceuticals/oncology/Controlling-CAR-T-scientists-plan/96/i19 "The two approved CAR-T therapies, Kymriah and Yescarta, target an antigen called CD19, found on B-cell cancers. Unfortunately, the CD19 protein is also located on healthy B cells, immune cells that produce protective antibodies. When CAR-Ts work, they kill all CD19-bearing cells, and thus all B cells. Because people can receive regular infusions of the antibodies that their missing B cells would normally make, doctors consider this collateral damage acceptable. But few other targets can be depleted wholesale without widespread harm." "Some researchers are careful to point out that overly complex systems will be difficult to turn into therapeutics. “The more bells and whistles you put into the system, the more ways there are for the system to fail,” says Yvonne Chen, a chemical engineer developing new CAR receptors at the University of California, Los Angeles. Widespread adoption of CAR-T therapy still has many challenges: streamlining manufacturing, reducing the risk of deadly side effects, and expanding the currently small patient population, to name a few. Yet just a few years ago, scientists “had real uncertainty about whether this could become a real therapeutic because of the logistical challenges,” says Glenn Dranoff, head of immuno-oncology at the Novartis Institutes for BioMedical Research. Scientists don’t know if CAR-Ts will ever be successful at treating more common cancers, but if the pace of innovation is any indication, hopes are high."
badger60
28/6/2018
14:28
Applegarth Ignore this clown......he shorts shares so simply goes around deramping what stocks he has taken a short out on.
cudmore
28/6/2018
14:14
Suppose it's covered, but you forgot the part that Car-t doesn't work on solid masses.
digittt
28/6/2018
13:49
just got all the share left at 3.5 but not show on the trade if it come up with approx. 150k share do not think someone that know what is doing is buying as it is me and I know nada
jovi1
28/6/2018
06:39
MANY THANKS FOR YOUR VALUABLE INPUT!!!.............I hear that they are also experimenting on cretins....….....you should volunteer.....
badger60
27/6/2018
23:48
IVE HEARD THEY ARE GOING TO EXPERIMENT ON ANTS SOON ??? OH AND DUCKS LOL !!!!!!!!!!!!!!!!!!! GIVE US SOME NEWS ! AGM HAS DONE NOTHING FOR SHARE HOLDER VALUE TODAY !!! LOTS UNDER WATER NOW !!! WE NEED THIS UP TO 6p AGAIN !!!!!!!!!!!!!!! MAKE IT HAPPEN GIVE US RNS !!!
applegarthlse
27/6/2018
20:24
Thanks badger60. Mine are tucked away but I now plan to keep adding when I can, before more investors arrive!
moormoney
27/6/2018
19:17
Looking ripe for a move northwards here
cudmore
27/6/2018
12:21
Fwiw my friend reckons that dependent on product development progress, the company will be bought out in 2/3 years. He's targeting a mkt cap of £75mio-£100mio if/when it happens.
badger60
27/6/2018
12:11
Cheers for that badger!
on target
Chat Pages: 56  55  54  53  52  51  50  49  48  47  46  45  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20180720 04:58:35